Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus.
about
Macrophage Heterogeneity and Plasticity: Impact of Macrophage Biomarkers on AtherosclerosisAccelerated atherosclerosis in patients with SLE--mechanisms and managementInterferon-alpha, immune activation and immune dysfunction in treated HIV infectionCardiovascular disease in lupus: insights and updates5-Aminolevulinic Acid-Mediated Sonodynamic Therapy Inhibits RIPK1/RIPK3-Dependent Necroptosis in THP-1-Derived Foam Cells.Type I interferon in the pathogenesis of lupus.Activation of type I interferon pathway in systemic lupus erythematosus: association with distinct clinical phenotypes.Type I interferons are associated with subclinical markers of cardiovascular disease in a cohort of systemic lupus erythematosus patients.Peptidylarginine deiminase inhibition reduces vascular damage and modulates innate immune responses in murine models of atherosclerosis.Monocyte activation from interferon-α in HIV infection increases acetylated LDL uptake and ROS productionMechanisms of premature atherosclerosis in rheumatoid arthritis and lupusInflammatory expression profiles in monocyte-to-macrophage differentiation in patients with systemic lupus erythematosus and relationship with atherosclerosis.The type I interferon system in the etiopathogenesis of autoimmune diseases.Roles of pro- and anti-inflammatory cytokines in the pathogenesis of SLEPathogenic immunity in systemic lupus erythematosus and atherosclerosis: common mechanisms and possible targets for interventionPlasmacytoid dendritic cells in atherosclerosis.Type I interferons modulate vascular function, repair, thrombosis, and plaque progression in murine models of lupus and atherosclerosisThe Therapeutic Potential for PI3K Inhibitors in Autoimmune Rheumatic DiseasesCardiovascular risk in pediatric-onset rheumatological diseases.Resveratrol counters systemic lupus erythematosus-associated atherogenicity by normalizing cholesterol efflux.Accelerated atherosclerosis in SLE: mechanisms and prevention approaches.Autoantigens: novel forms and presentation to the immune system.Prediction and management of cardiovascular outcomes in systemic lupus erythematosus.Type I IFNs as biomarkers in rheumatoid arthritis: towards disease profiling and personalized medicine.Inflammation-induced foam cell formation in chronic inflammatory disease.Cardiovascular comorbidity in rheumatic diseases.Why are kids with lupus at an increased risk of cardiovascular disease?Oxidized LDL activated eosinophil polarize macrophage phenotype from M2 to M1 through activation of CD36 scavenger receptor.Update on cardiovascular disease in lupus.Macrophages in vascular inflammation and atherosclerosis.How does interferon-α insult the vasculature? Let me count the waysArtesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.
P2860
Q26780531-7C69F736-34CB-4E30-A53E-7DA8F26C4A3EQ26820245-99FE5F1A-6AD4-4299-9137-215BACABCAE5Q26861003-9AF5638A-8874-4BC2-9BD6-80279923FBE7Q27016554-D6AAA262-5ECA-40F4-B998-470312C4953DQ30717193-B84D1AAE-5EAA-4E51-BB5B-B77D5C5665CBQ33852174-04780FA1-20B0-41E1-8556-E1F2013B6811Q34240254-86FB3F49-4523-428A-8734-7A27FF32A4CCQ34273836-2580BDB9-C188-4E73-9E87-032B624334B6Q34290113-3335AA3A-B32D-441D-B57B-8C35C2E1BEC7Q34292033-DE2BF783-35F9-49C1-8629-17DC0ADABF89Q34343906-055C1233-BE97-4762-BFE6-04865E5BBD27Q34487229-B3624662-A85F-4D3B-99F3-F97AD1018FC7Q35514368-FAE15FF0-9BE4-40B0-9E8E-0A0FE083BAAEQ35829864-0F1DAA54-D743-48DA-AA59-BA731551D2C3Q35998510-7833A856-BE30-4766-851C-AABE547AC7D2Q36064574-1BC102EF-BBBE-42D3-9C4F-C50475BAFFA4Q36139902-10AD4915-9AFD-4636-8FF0-A431B525A7E8Q36286414-643FD607-F85F-4258-8906-F90BE37C541EQ36903089-5F28A013-F735-485A-A2EE-8934C928BAE1Q37197627-339B59D6-BED6-40BB-ABC8-C905CA0C5DDEQ37658524-9AD0E83E-BF48-41D1-B8C9-17945EDEDB32Q38160040-FC7A94ED-4F43-440D-B7AD-90B0A6A52BA6Q38291820-8252DA66-E1C8-4F32-958B-049779E31284Q38335622-E2DE65C8-D49B-4515-87B8-35192A6F7029Q38370895-3FD1E316-0B28-4D1F-B33B-9836C92171E4Q38568465-2D9B182A-151C-44B0-AF64-AFFD58258950Q38591752-3D8EC83B-C02D-4750-969C-E8F1671A0A2FQ38721469-BFBA4BE1-1A4B-49A7-B88D-03461A5FCF8DQ38844782-FC1BD937-3F08-417A-9C4C-9B6CA0E09F1DQ39123553-9E36B9DE-0B62-484B-8253-4B9C7DCD7BBFQ42703913-99AFBE00-F904-4B0D-8A77-86A02311F700Q52867190-D718BFB5-1FE2-46BF-BC8E-D5A6F37C372D
P2860
Interferon-α priming promotes lipid uptake and macrophage-derived foam cell formation: a novel link between interferon-α and atherosclerosis in lupus.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Interferon-α priming promotes ...... and atherosclerosis in lupus.
@en
Interferon-α priming promotes ...... and atherosclerosis in lupus.
@nl
type
label
Interferon-α priming promotes ...... and atherosclerosis in lupus.
@en
Interferon-α priming promotes ...... and atherosclerosis in lupus.
@nl
prefLabel
Interferon-α priming promotes ...... and atherosclerosis in lupus.
@en
Interferon-α priming promotes ...... and atherosclerosis in lupus.
@nl
P2093
P2860
P356
P1476
Interferon-α priming promotes ...... and atherosclerosis in lupus.
@en
P2093
Chunde Bao
Huijuan Cui
P2860
P304
P356
10.1002/ART.30165
P577
2011-02-01T00:00:00Z